Glycopyrrolate Inhaled

Glycopyrrolate Inhaled is used for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

• Glycopyrrolate Inhaled is available under the following different brand names: Seebri Neohaler and Lonhala Magnair.

Common side effects of glycopyrrolate inhaled include:

• Upper respiratory tract infection
• Runny or stuffy nose
• Mouth pain and sore throat
• Urinary tract infection (UTI)
• Sinusitis

Seek medical care or call 911 at once if you have the following serious side effects:

• Severe headache, confusion, slurred speech, arm or leg weakness, trouble walking, loss of coordination, feeling unsteady, very stiff muscles, high fever, profuse sweating, or tremors;
• Serious eye symptoms such as sudden vision loss, blurred vision, tunnel vision, eye pain or swelling, or seeing halos around lights;
• Serious heart symptoms such as fast, irregular, or pounding heartbeats; fluttering in your chest; shortness of breath; sudden dizziness, lightheartedness, or passing out.

This document does not contain all possible side effects and others may occur. Check with your physician for additional information about side effects.

Dosages of Glycopyrrolate Inhaled:

Dosage Forms and Strengths

Encapsulated Powder for Oral Inhalation

• 15.6 mcg/capsule (Seebri Neohaler)

Solution for Oral Inhalation Via Nebulizer

• 25 mcg/mL vial (Lonhala Magnair)

Dosage Considerations – Should be Given as Follows:

Chronic Obstructive Pulmonary Disease (COPD)

• A long-acting muscarinic antagonist inhalant is indicated for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema
• Seebri Neohaler: Orally inhale contents of 1 capsule every 12 hours using the Neohaler device
• Lonhala Magnair: Orally inhale contents of 1 vial (25 mcg/mL) every 12 hours using the Magnair device

Dosage Modifications

• No dosage adjustment is required for geriatric patients, patients with mild and moderate hepatic impairment, or patients with mild-to-moderate renal impairment
• Severe renal or hepatic impairment: Not studied

Dosing Considerations

• Limitations of use: Not indicated for the relief of acute bronchospasm or the treatment of asthma
• Safety and efficacy not established in pediatric patients

If your doctor has directed you to use this medication, your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring you for them. Do not start, stop, or change the dosage of any medicine before checking with your doctor, health care provider, or pharmacist first.

• Severe interactions of glycopyrrolate inhaled include:
  • umeclidinium bromide/vilanterol inhaled
• Serious interactions of glycopyrrolate inhaled include:
  • glucagon
  • glucagon intranasal
  • pramlintide
  • revefenacin
  • Glycopyrrolate inhaled has moderate interactions with at least 97 different drugs.
• Mild interactions of glycopyrrolate inhaled include:
  • desipramine
  • dimenhydrinate
  • donepezil
  • galantamine
  • lofepramine
  • prochlorperazine
  • promazine
  • promethazine
  • rimantadine
  • thioridazine
  • trazodone
  • trifluoperazine

This document does not contain all possible interactions. Therefore, before using this product, tell your doctor or pharmacist about all the products you use. Keep a list of all your medications with you, and share the list with your doctor and pharmacist. Check with your physician if you have health questions or concerns.

Warnings

This medication contains glycopyrrolate inhaled. Do not take Seebri Neohaler or Lonhala Magnair if you are allergic to glycopyrrolate inhaled or any ingredients contained in this drug.
Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center immediately.

Contraindications

• Hypersensitivity

Effects of Drug Abuse

• No information is available

Short-Term Effects

• See "What Are Side Effects Associated with Using Glycopyrrolate Inhaled?”

Long-Term Effects

• See "What Are Side Effects Associated with Using Glycopyrrolate Inhaled?”

Cautions

• Should not be initiated in patients with acutely deteriorating or potentially life-threatening episodes of COPD; also, do not use for the relief of acute symptoms (i.e., as rescue therapy) for treating acute episodes of bronchospasm
• Can produce paradoxical bronchospasm that may be life-threatening
• Immediate hypersensitivity reactions have been reported after administration of indacaterol or glycopyrrolate
• Worsening of narrow-angle glaucoma or urinary retention may occur; use with caution in patients with prostatic hyperplasia, or bladder-neck obstruction and instruct patients to contact a physician immediately if symptoms occur

Drug interaction overview

• Concomitant use with anticholinergic medications may cause additive anticholinergic effects; if possible, avoid coadministration

Pregnancy and Lactation

There are no adequate and well-controlled studies of glycopyrrolate inhaled use during pregnancy in humans. Animal studies have not shown teratogenicity. Consult your doctor.

It is unknown if glycopyrrolate inhaled is distributed in human breast milk. Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for glycopyrrolate inhaled, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition.